yahoo_financeOriginal article
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
Phase 3Neutral
AI Analysis
Summary
CLDX stock declined 11% amid Phase 3 trial safety concerns, though an analyst contends these concerns are unfounded and sees nearly 90% upside potential.
Clinical Trial Data
Phase
3
Outcome Details
Safety concerns raised in Phase 3 trial
Importance:6/10
Sentiment:
0.20
Phase 3 TrialSafety ConcernsStock DeclineAnalyst Rating
Related Companies
Read the original article
Published by yahoo_finance on September 22, 2026 5:10 PM